HIKMA Pharmaceuticals PLC

Director's Dealing • Mar 15, 2022

National Storage Mechanism | Additional information

RNS Number : 8299E

Hikma Pharmaceuticals Plc

15 March 2022

Hikma Pharmaceuticals PLC - EIP C Vesting

LONDON, 15 March 2022: Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK) ("Hikma") (LEI: 549300BNS685UXH4JI75) announces that the following Persons Discharging Managerial Responsibility ("PDMR") have received shares as a result of the vesting of their conditional share awards which were granted on 12 March 2019 under the 2014 Executive Incentive Plan ("EIP") Element C.

Notification and public disclosure of transactions by persons discharging managerial responsibilities

Said Darwazah

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Said Darwazah
2	Reason for the notification
a)	Position/status	Executive Chairman
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Hikma Pharmaceuticals PLC
b)	LEI	549300BNS685UXH4JI75
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument and identification code	Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083
b)	Nature of the transaction	Shares acquired from the vesting of conditional awards on 14 March 2022 under the EIP Element C.  All Shares were retained.
c)	Price(s) and volume(s)	Price(s): £nil Volume(s): 38,862
d)	Aggregated information -       Volume -       Price -       Total	38,862 £0.00 £0.00
e)	Date of the transaction	14 March 2022
f)	Place of the transaction	London Stock Exchange (XLON)

Siggi Olafsson

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Sigurdur Olafsson
2	Reason for the notification
a)	Position/status	Chief Executive Officer
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Hikma Pharmaceuticals PLC
b)	LEI	549300BNS685UXH4JI75
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument and identification code	Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083
b)	Nature of the transaction	Shares acquired from the vesting of conditional awards on 14 March 2022 under the EIP Element C.  16,299 Shares were sold to cover tax and the remainder were retained.
c)	Price(s) and volume(s)	Price(s): £nil Volume(s): 26,377 Price(s): £19.88 Volume(s): 16,299
d)	Aggregated information -       Volume -       Price -       Total	42,676 £19.88 £324,024.12
e)	Date of the transaction	14 March 2022
f)	Place of the transaction	London Stock Exchange (XLON)

Siggi Olafsson

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Sigurdur Olafsson
2	Reason for the notification
a)	Position/status	Chief Executive Officer
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Hikma Pharmaceuticals PLC
b)	LEI	549300BNS685UXH4JI75
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument and identification code	Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083
b)	Nature of the transaction	The Company granted the named individual above a conditional award to acquire Shares under a bespoke arrangement in respect of the first year of service only that operates on the same basis as Element C of the 2014 Executive Incentive Plan (EIP). 27,498 Shares were sold to cover tax and the remainder were retained.
c)	Price(s) and volume(s)	Price(s): £nil Volume(s): 44,502 Price(s): £19.88 Volume(s): 27,498
d)	Aggregated information -       Volume -       Price -       Total	72,000 £19.88 £546,660.24
e)	Date of the transaction	14 March 2022
f)	Place of the transaction	London Stock Exchange (XLON)

Mazen Darwazah

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Mazen Darwazah
2	Reason for the notification
a)	Position/status	Executive Vice Chairman
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Hikma Pharmaceuticals PLC
b)	LEI	549300BNS685UXH4JI75
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument and identification code	Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083
b)	Nature of the transaction	Shares acquired from the vesting of conditional awards on 14 March 2022 under the EIP Element C.  All Shares were retained.
c)	Price(s) and volume(s)	Price(s): £nil Volume(s): 26,514
d)	Aggregated information -       Volume -       Price Total	26,514 £0.00 £0.00
e)	Date of the transaction	14 March 2022
f)	Place of the transaction	London Stock Exchange (XLON)

Riad Mishlawi

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Riad Mishlawi
2	Reason for the notification
a)	Position/status	PDMR
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Hikma Pharmaceuticals PLC
b)	LEI	549300BNS685UXH4JI75
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument and identification code	Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083
b)	Nature of the transaction	Shares acquired from the vesting of conditional awards on 14 March 2022 under the EIP Element C.  All Shares were retained.
c)	Price(s) and volume(s)	Price(s): £nil Volume(s): 23,030
d)	Aggregated information -       Volume -       Price -       Total	23,030 £0.00 £0.00
e)	Date of the transaction	14 March 2022
f)	Place of the transaction	London Stock Exchange (XLON)

Majda Labadi

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Majda Labadi
2	Reason for the notification
a)	Position/status	PDMR
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Hikma Pharmaceuticals PLC
b)	LEI	549300BNS685UXH4JI75
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument and identification code	Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083
b)	Nature of the transaction	Shares acquired from the vesting of conditional awards on 14 March 2022 under the EIP Element C.  All Shares were retained.
c)	Price(s) and volume(s)	Price(s): £nil Volume(s): 12,064
d)	Aggregated information -       Volume -       Price -       Total	12,064 £0.00 £0.00
e)	Date of the transaction	14 March 2022
f)	Place of the transaction	London Stock Exchange (XLON)

Bassam Kanaan

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Bassam Kanaan
2	Reason for the notification
a)	Position/status	PDMR
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Hikma Pharmaceuticals PLC
b)	LEI	549300BNS685UXH4JI75
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument and identification code	Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083
b)	Nature of the transaction	Shares acquired from the vesting of conditional awards on 14 March 2022 under the EIP Element C.  All Shares were retained.
c)	Price(s) and volume(s)	Price(s): £nil Volume(s): 19,195
d)	Aggregated information -       Volume -       Price -       Total	19,195 £0.00 £0.00
e)	Date of the transaction	14 March 2022
f)	Place of the transaction	London Stock Exchange (XLON)

Khalid Nabilsi

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Khalid Nabilsi
2	Reason for the notification
a)	Position/status	PDMR
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Hikma Pharmaceuticals PLC
b)	LEI	549300BNS685UXH4JI75
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument and identification code	Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083
b)	Nature of the transaction	Shares acquired from the vesting of conditional awards on 14 March 2022 under the EIP Element C.  All Shares were retained.
c)	Price(s) and volume(s)	Price(s): £nil Volume(s): 17,710
d)	Aggregated information -       Volume -       Price -       Total	17,710 £0.00 £0.00
e)	Date of the transaction	14 March 2022
f)	Place of the transaction	London Stock Exchange (XLON)

Brian Hoffmann

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Brian Hoffmann
2	Reason for the notification
a)	Position/status	PDMR
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Hikma Pharmaceuticals PLC
b)	LEI	549300BNS685UXH4JI75
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument and identification code	Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083
b)	Nature of the transaction	Shares acquired from the vesting of conditional awards on 14 March 2022 under the EIP Element C. 4,310 Shares were sold to cover tax and the remainder were retained.
c)	Price(s) and volume(s)	Price(s): £nil Volume(s): 6,975 Price(s): £19.88 Volume(s): 4,310
d)	Aggregated information -       Volume -       Price -       Total	11,285 £19.88 £85,682.80
e)	Date of the transaction	14 March 2022
f)	Place of the transaction	London Stock Exchange (XLON)

Susan Ringdal

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Susan Ringdal
2	Reason for the notification
a)	Position/status	PDMR
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Hikma Pharmaceuticals PLC
b)	LEI	549300BNS685UXH4JI75
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument and identification code	Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083
b)	Nature of the transaction	Shares acquired from the vesting of conditional awards on 14 March 2022 under the EIP Element C.  4,820 Shares were sold to cover tax and the remainder were retained.
c)	Price(s) and volume(s)	Price(s): £nil Volume(s): 5,383 Price(s): £19.88 Volume(s): 4,820
d)	Aggregated information -       Volume -       Price -       Total	10,203 £19.88 £95,821.60
e)	Date of the transaction	14 March 2022
f)	Place of the transaction	London Stock Exchange (XLON)

Henriette Nielsen

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Henriette Nielsen
2	Reason for the notification
a)	Position/status	PDMR
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Hikma Pharmaceuticals PLC
b)	LEI	549300BNS685UXH4JI75
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument and identification code	Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083
b)	Nature of the transaction	Shares acquired from the vesting of conditional awards on 14 March 2022 under the EIP Element C.  2,670 Shares were sold to cover tax and the remainder were retained.
c)	Price(s) and volume(s)	Price(s): £nil Volume(s): 4,320 Price(s): £19.88 Volume(s): 2,670
d)	Aggregated information -       Volume -       Price -       Total	6,990 £19.88 £53,079.60
e)	Date of the transaction	14 March 2022
f)	Place of the transaction	London Stock Exchange (XLON)

Peter Speirs

Company Secretary, responsible for releasing this announcement

+44 (0) 20 7399 2760

15 March 2022

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHBGGDXRUBDGDU